NRX Pharmaceuticals (NRXP) Non-Current Assets (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Non-Current Assets data on file, last reported at $4.5 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 1259.88% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $11.9 million, a 736.47% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, up 1064.47% from the prior year.
• Non-Current Assets for Q1 2026 stood at $4.5 million, up from $4.1 million in the prior quarter.
• Over the last five years, Non-Current Assets for NRXP reached as high as $4.5 million in Q1 2026 and fell as low as $17000.0 in Q1 2022.
• Historically, Non-Current Assets has averaged $843764.7 across 5 years, with a median of $334000.0 in 2025.
• Across the five-year window, Non-Current Assets tumbled 99.72% in 2022 and jumped 1952.38% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $21000.0 in 2022, then soared by 1952.38% to $431000.0 in 2023, then declined by 19.03% to $349000.0 in 2024, then jumped by 1064.47% to $4.1 million in 2025, then grew by 11.76% to $4.5 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $4.5 million in Q1 2026, $4.1 million in Q4 2025, and $3.0 million in Q3 2025.